Ojer Pharma is a biopharmaceutical company specialized in dermatology that develops innovative pharmaceutical products and disruptive dosage forms to improve efficacy and reduce toxicity. The company has launched products commercially (including Lavirk in Spain) and secured licensing agreements for Impetine in China and Keramod in Spain and Germany. It has also developed a dermatological veterinary line and continues investing in R&D and new vehiculization technologies. Leadership is headed by CEO and founder Carlos González, who brings 17 years of industry experience, and the team has deep pharmaceutical sector expertise. Financially, the company has completed multiple equity capital increases to support commercialization, regulatory work and product development. Ojer Pharma is a pharmaceutical company spun out of the University of Navarra in 2005 that develops prescription and over‑the‑counter products for dermatology. Its portfolio includes Lipovir®, a bioadhesive hydrogel delivering aciclovir for labial herpes, and Impetine®, a mupirocin bioadhesive lipogel co‑developed with Reig Jofré and in Phase III. The company planned Spanish market launches in 2014 for Previderm® and two Dermatul® products, and expected Lipovir® and Impetine® to reach the market in 2015. The recent financing led by Inveready is intended to finalize key developments and initiate commercial exploitation of high‑value dermatology products. Ojer Pharma is led by CEO Carlos González and has been previously financed by Sodena, Clave Mayor S.G.E.C.R., Ronda Vida F.C.R., Real de Vellón S.A. S.C.R. and other investors.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2023